Special issue of the Journal of Neuromuscular Diseases is devoted to the Treatabolome, designed to shorten diagnosis-to-treatment time for patients with rare diseases

In 2019, as part of the European Solve-RD project, Hanns Lochmüller, Gisèle Bonne and Rachel Thompson launched the Treatabolome, an initiative designed to extract details of effective treatments for rare diseases from the scientific literature and make them accessible through an online database that aims to allow patients to receive the right treatment for their condition as soon as they receive a genetic diagnosis.

The process of extracting reliable treatment information from scientific publications begins with a systematic review of the literature for each disease area to ensure that all the published information is captured. The Lochmüller Lab’s original systematic review of congenital myasthenic syndromes provided a comprehensive overview of the treatments available for these rare but often highly treatable diseases, which are one of our lab’s main focus areas.

This month, an open-access special issue of the Journal of Neuromuscular Diseases dedicated to the Treatabolome has been published. It includes six systematic reviews contributed by experts on rare neurological disorders, summarising the literature on each disease group and linking treatments with genotype and causative variants. Thanks to the team at CNAG in Barcelona behind the RD-Connect Genome-Phenome Analysis Platform, the data is also being transformed into an online database to be launched later this summer, which is intended to reduce treatment delays for patients with rare diseases by directly linking diagnosis and treatment information.

The special issue also includes a systematic review on the metabolic myopathies from our lab with Alex Manta, Sally Spendiff, Hanns Lochmüller and Rachel Thompson as co-authors.

You can find Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’  here.

Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a ‘Treatabolome’.
Manta A, Spendiff S, Lochmüller H, Thompson R.
J Neuromuscul Dis. 2021;8(3):401-417.
doi: 10.3233/JND-200621.
PMID: 33720849

 

Access the special issue of the Journal of Neuromuscular Diseases here.

Read the press release about the Treatabolome special issue here.

1by1treatabolome

Read next...

haleyozgefinal

Two Research Lab Members Receive CIHR Funding Awards!

We are excited to share that two of our research team members have received competitive funding awards from the Canadian Institutes of Health Research (CIHR)...
Hanns CRC image (1)

Dr. Hanns Lochmüller’s Canada Research Chair Renewed Through 2032

We are pleased to announce that Dr. Hanns Lochmüller’s Tier 1 Canada Research Chair (CRC) in Neuromuscular Genomics and Health has been renewed through the...
kiran scientist

Dr. Kiran Polavarapu Appointed Scientist at the CHEO Research Institute

We are delighted to congratulate Dr. Kiran Polavarapu on his appointment as Scientist at the Children’s Hospital of Eastern Ontario Research Institute (CHEO RI). This...
welcome

Meet The Lab’s New Clinical Members!

Our research team is growing! We are excited to announce three new research staff who have joined the lab this winter, as well as two...
researcher of the year 2025

Dr. Hanns Lochmüller Awarded “Clinical Researcher of the Year” by University of Ottawa Faculty of Medicine

We are thrilled to announce that Dr. Hanns Lochmüller has been awarded the Clinical Researcher of the Year Award by the University of Ottawa Faculty...
Holland study

New Publication: Galactose treatment rescues neuromuscular junction transmission in glutamine-fructose-6-phosphate transaminase 1 (Gfpt1) deficient mice

Congenital Myasthenic Syndromes (CMS) are a group of rare inherited neuromuscular disorders caused by genetic defects at the neuromuscular junction (NMJ). Patients with CMS experience...